抗CD22单克隆IgG抗体依帕珠单抗在伴干燥综合征的系统性红斑狼疮患者中的疗效:EMBODY试验事后分析
EMBODY 1和EMBODY 2试验共随机分配1,584例SLE患者,其中113例抗SSA阳性并诊断为伴发干燥综合征(SS),1,375例(86.8%)无伴发SS诊断。事后分析显示,仅在伴发SS的SLE患者中,依帕珠单抗组达到BICLA应答和BILAG总分较基线下降的患者比例高于安慰剂组。伴发SS患者B细胞下降更快,B细胞对依帕珠单抗的敏感性更高(50%最大B细胞计数耗竭的平均浓度9.5 μg/ml vs 总EMBODY人群87.1 μg/ml)。
要点
- EMBODY 1和2试验中,伴发SS的SLE患者接受依帕珠单抗后BICLA应答比例和BILAG总分较基线下降比例高于安慰剂。
- 伴发SS患者B细胞下降速度更快,50%最大B细胞计数耗竭的平均浓度为9.5 μg/ml,低于总EMBODY人群的87.1 μg/ml。
- 伴发SS的SLE患者经依帕珠单抗治疗后SLE疾病活动度改善,与B细胞数量和IgM水平下降等生物活性相关。
核心结论
- 伴发干燥综合征的SLE患者接受依帕珠单抗治疗后SLE疾病活动度改善,且与B细胞数量和IgM水平下降等生物活性相关。
研究设计与样本
- EMBODY 1(NCT01262365)和EMBODY 2(NCT01261793)试验的事后分析,共随机分配1,584例SLE患者,其中113例抗SSA阳性并诊断为伴发SS,1,375例(86.8%)无伴发SS诊断。
- 比较伴发SS与不伴发SS两个患者亚组中依帕珠单抗的疗效与安全性,评估BILAG总分、BICLA临床应答、生物标志物(包括B细胞、IgG、IgM、IgA)及安全性。
主要发现
- 对于伴发SS的患者,依帕珠单抗组达到BICLA应答和BILAG总分较基线下降的患者比例高于安慰剂组;不伴发SS的患者中未观察到该差异。
- 伴发SS患者B细胞下降更快。
- 以50%最大B细胞计数耗竭的平均浓度衡量,伴发SS患者对依帕珠单抗的B细胞敏感性更高(9.5 μg/ml vs 总EMBODY人群87.1 μg/ml)。
- 接受安慰剂者的不良事件频率未报告差异。
关键数值与推荐
- 伴发SS患者50%最大B细胞计数耗竭的平均浓度为9.5 μg/ml,总EMBODY人群为87.1 μg/ml。
- EMBODY 1和EMBODY 2试验共随机分配1,584例患者,其中伴发SS者113例,无伴发SS诊断者1,375例(86.8%)。
- 918例患者随机接受依帕珠单抗,457例接受安慰剂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: EMBODY 1 (ClinicalTrials.gov identifier: NCT01262365) and EMBODY 2 (ClinicalTrials.gov identifier: NCT01261793) investigated the efficacy and safety of epratuzumab, a CD22-targeted humanized monoclonal IgG antibody, in patients with systemic lupus erythematosus (SLE). The studies showed no significant difference from placebo in primary or secondary clinical outcome measures but did demonstrate B cell-specific immunologic activity. The aim of this post hoc analysis was to determine whether epratuzumab had a different clinical efficacy profile in SLE patients with versus those without an associated diagnosis of Sjögren's syndrome (SS). METHODS: The efficacy and safety of epratuzumab were compared between 2 patient subpopulations randomized in EMBODY 1 and 2: SLE patients with and those without a diagnosis of associated SS. British Isles Lupus Assessment Group (BILAG) total score, BILAG-based Combined Lupus Assessment (BICLA) clinical response to treatment, biologic markers (including B cells, IgG, IgM, and IgA), and safety were assessed. RESULTS: A total of 1,584 patients were randomized in the EMBODY 1 and EMBODY 2 trials; 113 patients were anti-SSA positive and had a diagnosis of associated SS, and 1,375 patients (86.8%) had no diagnosis of associated SS (918 patients were randomized to receive epratuzumab and 457 to receive placebo). For patients with associated SS, but not those without associated SS, a higher proportion of patients receiving epratuzumab achieved a BICLA response and a reduction from baseline in BILAG total score. B cell reduction was faster in patients with associated SS. The sensitivity of B cells to epratuzumab as measured by the mean concentration producing 50% of the maximum B cell count depletion was lower for patients with associated SS (9.5 μg/ml) versus the total EMBODY population (87.1 μg/ml). No difference in the frequency of adverse events in those receiving placebo was reported. CONCLUSION: Patients with SLE and associated SS treated with epratuzumab showed improvement in SLE disease activity, which was associated with bioactivity, such as decreases in B cell number and IgM level.
引用
- Gottenberg JE, Dörner T, Bootsma H, et al. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials. Arthritis Rheumatol. 2018. PMID: 29381843. doi:10.1002/art.40425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。